Anyone suffering from Type 2 diabetes understands the importance of keeping your blood glucose levels down. Some individuals are able to control their blood glucose levels through a combination of exercise and healthy eating. Yet others need more to bring their blood glucose down near the normal range. For them, the next step is taking a medicine that lowers their blood glucose levels.
The drug Onglyza (saxagliptin), manufactured by biopharmaceutical company AstraZeneca Pharmaceuticals LP, is a popular diabetes drug that has been largely successful in helping patients achieve just that. Yet, Onglyza isn’t without controversy. Use of the drug has been linked to numerous health complications such as an increased risk of heart failure and pancreatic cancer. Hundreds of Onglyza lawsuits have been filed across the country for various reasons. Most notably claiming wrongful death and that the manufacturer failed to properly warn an Illinois woman of Onglyza’s potentially dangerous side effects linked to heart failure.
If you are taking Onglyza, speak to your doctor right away before discontinuing use of the drug. The following is a general overview of Onglyza lawsuits, concentrating on heart failure, with information about other pending lawsuits throughout the country.
Onglyza first came onto the pharmaceutical scene in 2009 when the Food and Drug Administration (FDA) gave its seal of approval for use in humans. By 2012, Onglyza, had sales of $709 million and became a key product for AstraZeneca.
However, treating physicians began to voice concern about the drug’s safety after an FDA study titled “SAVOR” or Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus, found that those who took Onglyza had a 27-percent greater risk of serious medical complications such as congestive heart failure. In April 2015, the FDA issued a statement recommending that a warning label be placed upon the drug indicating an increased risk for heart failure, particularly for patients with a history of heart or kidney disease.
Onglyza Lawsuits: Heart Failure
The first lawsuit to be filed relating to heart failure is currently pending in the Cook County Circuit Court in the state of Illinois. Rochelle Gibson, daughter of Lillie Ree Gibson, filed a wrongful death lawsuit on behalf of her mother, who died in October 2013 after taking Onglyza. Gibson was prescribed the drug in 2010. Her first bout with heart failure occurred in June 2011 and she was hospitalized twice before dying as a result of complications.
You may be eligible for compensation if you or a loved one has suffered injuries or death after using Onglyza. Keep in mind, if left untreated, type 2 diabetes can lead to serious health problems. Please speak to your doctor right away if you have questions or concerns.
Onglyza Lawsuits: Pancreatic Cancer
In addition to heart failure, persons who took other dipeptidyl-peptidase 4 (DPP-4) inhibitors (similar to Onglyza) also claim to have suffered pancreatic cancer as a result of taking these drugs. Hundreds of lawsuits have been filed in California against those manufacturers and have been consolidated into a multidistrict litigation lawsuit.
Contact an Attorney to Discuss Your Onglyza Claim
If you or a loved one has suffered adverse side effects related to Onglyza, you may be eligible to initiate a product liability or wrongful death lawsuit against the drugmaker, AstraZeneca. A good first step in that process is to contact an experienced attorney familiar with this issue who can give a recommendation on a potential Onglyza legal action.
Contact a qualified product liability attorney to make sure your rights are protected.